8月20日，先声药业发布2026年中期业绩公告。上半年，公司实现收入45.8亿元，较2025年同期的35.85亿元增长27.8%；创新药业务收入为38.87亿元，占总收入比率为84.9%，较2025年同期增长34.1%；归属于公司权益股东的利润为8.29亿元，较2025年同期增长37.9%；经调整归属于公司权益股东的利润为9.64亿元，较2025年同期增长48.7%。（文章来源：北京商报）
Source Link8月20日，先声药业发布2026年中期业绩公告。上半年，公司实现收入45.8亿元，较2025年同期的35.85亿元增长27.8%；创新药业务收入为38.87亿元，占总收入比率为84.9%，较2025年同期增长34.1%；归属于公司权益股东的利润为8.29亿元，较2025年同期增长37.9%；经调整归属于公司权益股东的利润为9.64亿元，较2025年同期增长48.7%。（文章来源：北京商报）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.